kangaSue
Senior Member
- Messages
- 1,851
- Location
- Brisbane, Australia
Ardelyx Receives FDA Approval for IBSRELA® (Tenapanor), an NHE3 Sodium Transport Inhibitor, for the Treatment of Irritable Bowel Syndrome with Constipation
https://www.prnewswire.com/news-rel...wel-syndrome-with-constipation-300917407.html
NHE3 transporter is primarily responsible for the absorption of dietary sodium. Inhibiting the NHE3 transporter is designed to reduce the absorption of dietary sodium in the bloodstream.
Tenapanor (IBSRELA) is a minimally-absorbed small molecule that acts locally in the gastrointestinal (GI) tract to inhibit the sodium-hydrogen exchanger NHE3, resulting in there being more sodium in the gut, which increases fluid being drawn into the bowel, and loosens stool in turn to effect an increase in bowel movements.
Tenapanor has also been shown to reduce abdominal pain by decreasing visceral hypersensitivity in IBS-C patients.
Other competing products (secretagogues) already on the market for constipation are Ironwood Pharmaceutical’s Linzess (linaclotide) and Synergy Pharmaceuticals’s Trulance (plecanatide).
https://www.prnewswire.com/news-rel...wel-syndrome-with-constipation-300917407.html
NHE3 transporter is primarily responsible for the absorption of dietary sodium. Inhibiting the NHE3 transporter is designed to reduce the absorption of dietary sodium in the bloodstream.
Tenapanor (IBSRELA) is a minimally-absorbed small molecule that acts locally in the gastrointestinal (GI) tract to inhibit the sodium-hydrogen exchanger NHE3, resulting in there being more sodium in the gut, which increases fluid being drawn into the bowel, and loosens stool in turn to effect an increase in bowel movements.
Tenapanor has also been shown to reduce abdominal pain by decreasing visceral hypersensitivity in IBS-C patients.
Other competing products (secretagogues) already on the market for constipation are Ironwood Pharmaceutical’s Linzess (linaclotide) and Synergy Pharmaceuticals’s Trulance (plecanatide).